Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Novel cxcr4 antagonist of amino acid skeleton and its preparation and biomedical application

A drug and pharmaceutical technology, applied in the direction of anti-inflammatory agents, antiviral agents, drug combinations, etc., to achieve the effect of novel structure and excellent antagonistic activity

Active Publication Date: 2021-01-22
TSINGHUA UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Currently, only one CXCR4 antagonist, plerixafor (AMD3100), has been approved by the FDA as a hematopoietic stem cell mobilizer, combined with granulocyte colony-stimulating factor (G-CSF) for multiple myeloma and Patients with non-Hodgkin's lymphoma are far from being able to meet clinical needs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel cxcr4 antagonist of amino acid skeleton and its preparation and biomedical application
  • Novel cxcr4 antagonist of amino acid skeleton and its preparation and biomedical application
  • Novel cxcr4 antagonist of amino acid skeleton and its preparation and biomedical application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0085] Example 1 Preparation of intermediate 1-3a (HFX50626-5): refer to the enumerated intermediate synthesis route (1)

[0086] 4-cyanobenzaldehyde (10g) was dissolved in methanol (150mL), and N-(3-aminopropyl)cyclohexylamine (12.4mL) and appropriate amount were added to the solution Molecular sieves, the reaction solution was heated to 65°C and stirred for 6 hours. After the reaction solution was cooled to room temperature, sodium borohydride (5.8 g) was added in batches and stirred at room temperature for 1-2 hours. The reaction was quenched with saturated ammonium chloride solution, and the reaction solution was concentrated to dryness. The residue was ultrasonically washed with methanol, filtered, and the filtrate was collected and evaporated to dryness to obtain intermediate 1-1a, which was directly used in the next reaction.

[0087] The crude intermediate 1-1a above was directly dissolved in tert-butanol (100mL) and sodium carbonate solution (2mol / L, 100mL), and Bo...

Embodiment 2

[0089] The preparation of embodiment 2 intermediate 1-3b

[0090] Referring to the enumerated intermediate synthesis route (1), the synthesis method and conditions are similar to the preparation of intermediate 1-3a.

Embodiment 3

[0091] Example 3 Preparation of intermediate 2-3a: refer to the enumerated unnatural amino acid synthesis route (2)

[0092] The amino acid raw material Fmoc-L-Lys(Boc)-OH (5 g) was weighed and suspended in dichloromethane (40 mL), and trifluoroacetic acid (20 mL) was added. After the reaction solution was stirred at room temperature for 1-2 hours, it was spin-dried, and the residue was precipitated with glacial ether. The resulting white precipitate was intermediate 2-1a, which was directly dissolved in methanol (50 mL), and acetone (20 mL) and trifluoroacetic acid (2 mL) were added. After stirring at room temperature for 2 hours, sodium triacetoxyborohydride (11.3 g) was added, and the stirring reaction was continued overnight. The final reaction solution was adjusted to PH 4-6 with hydrochloric acid solution (4mol / L), the concentration reached a certain volume, and extracted with ethyl acetate. The combined organic phases were dried with anhydrous sodium sulfate, filtered...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention proposes a compound represented by formula (I) or a pharmaceutically acceptable salt or prodrug thereof. The compound has a novel structure, high efficiency and low toxicity, and has excellent CXCR4 antagonistic activity, which can block HIV from invading and infecting human target cells or treat or prevent AIDS or mobilize human bone marrow hematopoietic cells, mesenchymal stem cells and stem cells or interfere with CXCL12 / CXCR4-mediated Cell migration and adhesion or prevention, treatment of tumor metastasis, invasion and growth mediated by CXCR4 or block CXCL12 / CXCR4 mediated autoimmunity and inflammatory response; and this type of compound can be used as an effective drug in the pharmaceutical composition The components can be used in combination with other anti-HIV drugs to prevent and treat HIV or in combination with other drugs used for treatment or prevention of leukemia, lymphoma, myeloma and solid tumors to prevent and treat tumors.

Description

technical field [0001] The invention relates to the field of medicinal chemistry, in particular, the invention relates to a novel CXCR4 antagonist of amino acid skeleton and its preparation and biomedical application. Background technique [0002] Chemokine receptors are a G protein-coupled receptor (GPCR) superfamily with seven transmembrane domain structures, and are usually expressed on the cell membranes of immune cells, epithelial cells, vascular endothelial cells, and nerve cells. One of the CXC chemokine receptors, CXCR4, and its natural ligand, the chemokine CXCL12 (stromal cell-derived factor-1, SDF-1), are widely expressed in a variety of cells and tissues, and they regulate the human immune system and circulatory system. It plays an important role in the nervous system, and their interaction and the signal transduction they mediate are closely related to various diseases such as viral infection, tumor development and metastasis, inflammation and autoimmune disease...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D213/38C07D215/40C07D233/24C07D401/12C07D401/06C07C279/14A61K31/4439A61K31/4709A61K31/4402A61K31/47A61K31/417A61K31/165A61P31/18A61P35/02A61P35/00A61P35/04A61P37/06A61P29/00C07K5/065C07K5/068A61K38/05
CPCA61K38/05A61P29/00A61P31/18A61P35/00A61P35/02A61P35/04A61P37/06C07C279/14C07D213/38C07D215/40C07D233/24C07D401/06C07D401/12C07D213/56C07D233/64A61K45/06A61K31/165A61K31/417A61K31/4402A61K31/4439A61K31/47
Inventor 黄子为方雄孟倩徐岩朱思雨方笑
Owner TSINGHUA UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com